Open AccessAlendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age
Author(s) -
Denise L. Jacobson,
Jane C. Lindsey,
Catherine M. Gordon,
Rohan Hazra,
Hans Spiegel,
Flávia V Ferreira,
Fabiana Rezende Amaral,
Jesica Pagano-Therrien,
Aditya H. Gaur,
Kathy George,
Jane E. Benson,
George K. Siberry
Publication year - 2019
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciz957
Subject(s) - medicine , bone mineral , osteoporosis , placebo , bisphosphonate , vitamin d and neurology , bone density , pediatrics , surgery , alternative medicine , pathology
Children and adolescents with perinatal human immunodeficiency virus (HIV) infection and with low bone mineral density (BMD) may be at higher risk of osteoporosis and fractures in later life than their uninfected peers. Bisphosphonate therapy has been shown to reduce fractures in adults with osteoporosis, but has not been formally studied in youths living with HIV.